US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Class II · Moderate risk Ongoing

R.E.C.K.

Reason Presence of Particulate Matter

QuVa Pharma, Inc. NDC 70092-1433-50 D-0113-2026
Class II · Moderate risk Ongoing

Hadlima

Reason Lack of Assurance of Sterility.

Samsung Bioepis Co., Ltd. NDC 78206-183-01 D-0099-2026
Class II · Moderate risk Ongoing

Gabapentin Capsules

Reason Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .

The Harvard Drug Group LLC NDC 0904-6665-61 D-0031-2026
Class II · Moderate risk Ongoing

Gabapentin Capsules

Reason Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .

The Harvard Drug Group LLC NDC 0904-6665-61 D-0030-2026
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.

Breckenridge Pharmaceutical, Inc. NDC 51991-748-10 D-0100-2026
Class II · Moderate risk Ongoing

Olopatadine Hydrochloride Ophthalmic Solution USP 0.1 %

Reason Failed Impurities/Degradation Specifications: The result for 'Any individual unspecified impurity' exceeds the specification limit.

USV Private Limited NDC 70512-0520-05 D-0034-2026
Class II · Moderate risk Ongoing

Sucralfate Tablets

Reason CGMP Deviations: The recalling firm filed for Chapter 11 on September 30, 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.

Amerisource Health Services LLC NDC 60687-695-01 D-0027-2026
Class II · Moderate risk Ongoing

Fasenra

Reason Lack of Assurance of Sterility:

Astrazeneca Pharmaceuticals NDC 0310-1730-30 D-0028-2026
Class II · Moderate risk Ongoing

Prazosin Hydrochloride

Reason CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.

Teva Pharmaceuticals USA, Inc NDC 0093-4069-01 D-0106-2026
Class II · Moderate risk Ongoing

Prazosin Hydrochloride

Reason CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.

Teva Pharmaceuticals USA, Inc NDC 0093-4068-01 D-0105-2026
Class II · Moderate risk Ongoing

Prazosin Hydrochloride

Reason CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.

Teva Pharmaceuticals USA, Inc NDC 0093-4067-01 D-0104-2026
Class II · Moderate risk Ongoing

Carbidopa

Reason Product mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5 mg/150 mg/200 mg) instead of labelled lower strength Carbidopa, Levodopa, and Entacapone film-coated tablets (25 mg/100 mg/200 mg).

Rising Pharma Holding, Inc. NDC 16571-691-01 D-0029-2026
Class II · Moderate risk Ongoing

Desipramine Hydrochloride Tablets

Reason CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Heritage Pharmaceuticals Inc NDC 23155-583-25 D-0112-2026
Class II · Moderate risk Ongoing

Desipramine Hydrochloride Tablets

Reason CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Heritage Pharmaceuticals Inc NDC 23155-582-01 D-0111-2026
Class II · Moderate risk Ongoing

Desipramine Hydrochloride Tablets

Reason CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Heritage Pharmaceuticals Inc NDC 23155-581-01 D-0110-2026
Class II · Moderate risk Ongoing

Desipramine Hydrochloride Tablets

Reason CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Heritage Pharmaceuticals Inc NDC 23155-580-01 D-0109-2026
Class II · Moderate risk Ongoing

Desipramine Hydrochloride Tablets

Reason CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Heritage Pharmaceuticals Inc NDC 23155-579-01 D-0108-2026
Class II · Moderate risk Ongoing

Desipramine Hydrochloride Tablets

Reason CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Heritage Pharmaceuticals Inc NDC 23155-578-01 D-0107-2026
Class II · Moderate risk Ongoing

Tavaborole Topical solution 5%

Reason Discoloration

Viona Pharmaceuticals INC NDC 72578-102-04 D-0016-2026
Class II · Moderate risk Ongoing

Testo-100 Ciii

Reason Lack of Assurance of Sterility: Potential microbial contamination of subcutaneous pellets.

Advanced Pharmaceutical Technology, Inc. NDC 57377-100-01 D-0258-2026
Class II · Moderate risk Ongoing

Zicam" Medicated Fruit Drops Elderberry Flavor

Reason Labeling: Label Mix-up: The product in the bottle contains elderberry and the label failed to indicate the inclusion of elderberry as an ingredient.

Church & Dwight Co., Inc. NDC 10237-469-25 D-0095-2026
Class II · Moderate risk Ongoing

Ketorolac Tromethamine Injection

Reason Presence of Particulate Matter: Particulate matter identified as glass

Aspiro Pharma Limited NDC 31722-307-25 D-0036-2026